

**ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS**

1. Salloway S, Price L, Charney D, Shapiro M. Multiple sclerosis Presenting as major depression: A diagnosis suggested by MRI but not CT Scan. *J Clin Psychiatry* 1988; 364-366.
2. Salloway S, Southwick S, Sadowsky M. Opiate withdrawal Presenting as post-traumatic stress disorder. *Hospital and Community Psychiatry* 1990;41:666-7.
3. Fogel B, Salloway S, McNamara E, Duffy J. Skeptics and enthusiasts in neuropsychiatry *J. Neuropsychiatry and Clin Neurosci* 1992;4:458-462.
4. Karper L, Salloway S, Seibyl J, Krystal J. Prolonged post-ictal encephalopathy in two patients following clozapine-induced seizures. *J Neuropsychiatry and Clin Neurosci* 1992;4:454-457.
5. Daly J, Salloway S. Clozapine-induced seizures and EEG changes. *Jefferson Journal of Psychiatry* 1993; 11:36-42.
6. Salloway S, Tate C, Rogg J. Clinicopathological case conference: Behavior change, hallucinations and memory loss in a twenty-five year old man. *J Neuropsychiatry and Clin Neurosci* 1993; 5:435-441.
7. Salloway S, Cummings J, Subcortical disease and neuropsychiatric illness. *J Neuropsychiatry and Clin Neurosci* 1994;6:93-99.
8. Daly J, Salloway S. Dopamine receptors in the human brain. *Psychiatric Times* 1994;11:27-32.
9. Campbell J, Duffy J, Salloway S. Treatment strategies for dysexecutive syndromes. *J Neuropsychiatry Clin Neurosci* 1994;6:411-418.
10. Salloway S. Diagnosis and treatment of patients with frontal lobe syndromes. *J Neuropsychiatry and Clin Neurosci* 1994;6:388-398.
11. Coffey CE, Cummings JL, Duffy J, Fink M, Lauterbach EC, Lovell M, Malloy P, Nussbaum P, Royall, DR, Salloway S. Assessment of treatment outcomes in neuropsychiatry. *J. Neuropsychiatry and Clin Neurosci* 1995;7:287-289.
12. Salloway S, Malloy P, Rogg J, Kohn R, Duffy J, Tung G, Thomas C, Richardson E, Gillard E, Westlake R. MRI and neuropsychological differences in early and late-life onset geriatric depression. *Neurology* 1996;46:1567-1574.
13. Salloway S. Clinical-Pathological Case Conference: Depression, behavior change and subcortical dementia in a 57-year-old woman. A case of biopsy-proven CADASIL syndrome. *J Neuropsychiatry and Clin Neurosci* 1996,8:215-221.
14. Salloway S, Cummings J. Subcortical structures and neuropsychiatric disorders. *The Neuroscientist* 1996;2:66-75.
15. Salloway S, Stewart CF, Morales X, Israeli L, Rasmussen S, Brin MF, Blitzer A. Botulinum toxin for refractory vocal tics. *Movement Disorders* 1996;11: 746-748.
16. Cahn D, Malloy P, Salloway S, Rogg J, Kohn R, Gillard E, Tung G, Richardson E. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *J Neuropsychiatry and Clin Neurosci* 1996;8:404-411.

17. Jenkins M, Salloway S, Westlake R. The diagnosis and treatment of geriatric depression. *Journal of Practical Psychiatry and Behavioral Health* 1996;6:336-349.
18. Salloway S, Mermel LA, Aspinall GO, Mam Shin JE, Kurjanczyk LA, Seamans M, Penner JL. Miller Fisher Syndrome associated with *Campylobacter* Jejuni bearing lipopolysaccharide molecules mimicking human ganglioside GD 3. *Infection and Immunity* 1996;64:2945-2949.
19. Harrington C, Salloway S, Malloy P. Dramatic neurobehavioral disorder in two cases following anteromedial frontal lobe injury: delayed psychosis and marked change in personality. *Neurocase* 1997;3:137-149.
20. Jenkins M, Cimino C, Malloy P, Salloway S, Cohen R, Kohn R, Westlake R. Neuropsychiatric factors in the illusion of visitors among geriatric patients: a case series. *J Geriatric Psychiatry and Neurology* 1997;10:79-87.
21. Salloway S, White J. Paroxysmal limbic disorders in neuropsychiatry. *J Neuropsychiatry Clin Neurosci* 1997;9:493-509.
22. Mega M, Cummings C, Salloway S, Malloy P. The limbic system:an anatomic, phylogenetic, and clinical perspective. *J Neuropsych Clin Neurosci* 1997;9:405-420.
23. Jenkins M, Cohen R, Malloy P, Salloway S, Gillard E, Penn J, Neeper R. Neuropsychology measures discriminate among adults with residual ADD and other attentional complaints. *The Clinical Neuropsychologist*, 1998;12:74-83.
24. Jenkins M, Malloy P, Salloway S, Cohen R, Gillard E, Kohn R, Rogg J, Tung G. Frontal-subcortical contributions to memory: Evidence from geriatric depressed patients with subcortical hyperintensities on MRI. *Journal of Neuroimaging* 1998, 8:20-26.
25. Kleiner-Fisman GK, Salloway S, Fisman SN. Recollection of childhood sexual abuse following endotracheal intubation. *Psychosomatics* 1998;39:561-2.
26. Cohen R, Kaplan R, Zuffante P, Moser D, Jenkins M, , Salloway S, Wilkinson H. Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy. *J Neuropsych Clin Neurosci* 1999;11:444-453.
27. Cahn-Weiner D, Malloy P, Boyle P, Marran M, Salloway S. Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals. *The Clinical Neuropsychologist* 2000; 14:187-195.
28. Norton L, Malloy PF, Salloway S. The impact of behavioral symptomatology on activities of daily living in patients with dementia. *Am J Geriatr Psych* 2001;9:1-8.
29. Salloway S, Boyle P, Correia S, Malloy P, Cahn-Weiner D, Schneider L, K. Krishnan R, Nakra R. The relationship of MRI subcortical hyperintensities to treatment response in a placebo-controlled trial of sertraline in geriatric depressed outpatients. *Am J Ger Psych*, 2002;10:107-111.
30. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Tavares R, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, Stopa E. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. *J Neurological Sciences* 2002;203-204:183-187.

31. Salloway S, Correia S, Boyle P, Malloy P, Schneider L, Lavretsky H, Sackheim H, Roose S, Krishnan KRR. MRI subcortical hyperintensities in old and very-old depressed outpatients: the important role of age in late-life depression. *J Neurological Sciences* 2002;203-4:227-233.
32. Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance and caregiver burden in Alzheimer's disease. *Alzheimer's Disease and Associated Disorders* 2002, Oct-Dec;16(4):248-53.
33. Boyle P, Malloy P, Salloway S, Cummings J. Executive dysfunction and apathy predict functional impairment in Alzheimer's disease. *Am J Ger Psych* 2003;11:214-221.
34. Black S, Roman G, Geldmacher D, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled trial. *Stroke* 2003;34:2323- 2332.
35. Malloy P, Belanger H, Hall S, Aloia M, Salloway S. Assessing visuoconstructional performance in AD, MCI and normal elderly using the Berry Visual-Motor Integration Test. *The Clinical Neuropsychologist*, 2003;17:544-550.
36. Salloway S, Stopa S, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and fluctuating leukoencephalopathy. *J Neurological Sciences* 2005, in press.
37. Salloway S, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial, *Neurology* 2004;63:651-657.
38. Belanger H, Wilder-Willis K, Malloy P, Hamman R, Salloway S, Grigsby J. Assessing motor and cognitive regulation in Alzheimer's disease, mild cognitive impairment and normal elderly using the behavioral dyscontrol scale. *Archives of Clinical Neuropsychology* 2005;20:183-189.
39. Maclean A, Correia S, Woods R, Stopa E, Cortez S, Alderson L, Salloway S. Spontaneous lobar hemorrhage in CADASIL. *J Neurology Neurosurgery and Psychiatry* 2005;76:456-7.
40. Roman G, Wilkinson D, Doody R, Black S, Salloway S, Schindler R. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dementia and Geriatric Cognitive Disorders*, 2005,20:338-344.
41. Steffens D, Otey E; Alexopoulos G; Butters M; Cuthbert B; Ganguli M; Geda Y; Hendrie H; Krishnan R, Kumar A; Lopez O; Lyketsos C; Mast B; Morris J; Norton C; Peavy G; Petersen R; Reynolds C; Salloway S; Welsh-Bohmer K; Yesavage J. Perspectives on depression, mild cognitive impairment, and cognitive decline. *Arch Gen Psychiatry* 2006;63:130-138.
42. Grundman M, Petersen R, Bennett D, Feldman H, Salloway S, Jelle-Visser P, Thal L, Schenk D, Khachaturian Z, Thies W, for the Alzheimer's Association Research Roundtable. Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? *Alzheimer's and Dementia* 2006, in press.

43. Salloway S, Correia S, Richardson S. Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnesic MCI. *Int Psychogeriatrics* 2008;20:40-46.
44. Greenberg BD, Malone DA, Rezai AR, Friehs GM, Kubu CS, Malloy PF, Salloway SP, Machado AG, Okun MS, Goodman WK, Rasmussen SA. Three year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder: *Neuropsychopharmacology* 2006;31:2384-93.
45. Fillit H, Doody RS, Binaso K, Crooks G, Ferris S, Farlow M, Leifer B, Mills C, Minkoff N, Orland B, Reichman W, Salloway S. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. *Am J Geriatric Pharmacother* 2006;4 Suppl A:S9-S24.
46. Salloway S. Buying time: Management of mild cognitive impairment and early dementia. *Int Psychogeriatr.* 2006 Sep;18 Suppl 1:S17-23.
47. Laidlaw DH, Lee SY, Correia S, Tate DF, Paul RH, Zhang S, Salloway SP, Malloy PF. Quantitative tract-of-interest metrics for white matter integrity based on diffusion tensor MRI data. *Views Radiology* 2007;8:2-4.
48. Cohen R, Butala P, Salloway S, Gonzalez L, Johansen C, Tovares R, Hovanesian V, Hulette C, Vitek M, Stopa E. Cerebral arteriolar angiopathy, Braak Stage, vascular  $\beta$ -amyloid and APOE genotype, *Stroke* 2008;39:in press.
49. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De DeynPP, Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. *Neurology* 2007;69:448-458.
50. Dubois B, Feldman H, Jacova C, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, Morris J, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser P, Scheltens P. Research criteria for diagnosing Alzheimer's disease: Revising the NINCDS-ADRDA Criteria. *Lancet Neurology* 2007;6:734-746.
51. Salloway S, Mintzer J, Weiner M, Cummings J. Disease modifying therapies for Alzheimer's disease, *Alzheimer's and Dementia*;2008,4:65-79.
52. Dichgans M, Markus H, Salloway S, Verkkoniemi A, Wang Q, Moline M, Posner H, Chabriat H. Donepezil in subcortical vascular cognitive impairment: a randomized double blind trial in CADASIL. *Lancet Neurology* 2008, in press.
53. Salloway S, Correia S. One hundred years of Alzheimer's disease: Time to improve diagnosis and treatment in primary care. *Cleveland Clinic Journal of Medicine*; 2008, in press.
54. Malone D, Greenberg B, Salloway S. Deep Brain Stimulation of the Ventral Internal Capsule/Ventral Striatum for Obsessive-Compulsive Disorder: Worldwide Experience. *Molecular Psychiatry* 2008, in press.
55. Correia S, Lee S, Tate D, Paul R, Zhang S, Salloway S, Malloy P, Laidlaw D. Quantitative tractography metrics for white matter integrity based on diffusion tensor MRI data. *Neuroimage* 2008, in press.

**OTHER PEER-REVIEWED PUBLICATIONS:**

1. Salloway S, Malloy P, Duffy J. The frontal lobes and neuropsychiatric illness. *J Neuropsychiatry Clin Neurosci* 1994;6:341-2.
2. Salloway S, Daly J. The neurochemistry of Alzheimer's disease. In: Richter R, ed. *Alzheimer's disease: A guide to clinical management*. New York, Mosby Press, 1996; 256-284. (Book Chapter)
3. Greenblatt S, Salloway S. Clinical examination of cognitive functions. In: Wilkins RH, Rengachary SS, eds. *Neurosurgery* 2nd ed. New York, McGraw-Hill 1996;49-58. (Book Chapter)
4. Saver J, Salloway S, Bear D, Devinsky O. Neuropsychiatry of aggression. In: Fogel B, Schiffer R, Rao S, eds. *Neuropsychiatry*. Baltimore, Williams and Wilkins 1996;523-548. (Book Chapter)
5. Cohen R, Salloway S. Disorders of attention In: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 3rd edition. Washington D.C., American Psychiatric Press 1997:413-446. (Book Chapter)
6. Mega M, Cummings J, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic and clinical perspective, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, Salloway S, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press, 1997, 3-18. (Book Chapter)
7. Salloway S, White J. Paroxysmal limbic disorders in neuropsychiatry, In: *The Neuropsychiatry of Limbic and Subcortical Disorders*, Salloway S, Malloy P, Cummings J. Washington, D.C., American Psychiatric Press, 1997, 95-112. (Book Chapter)
8. Malloy PM, Cummings JL, Coffey CE, Duffy J, Fink M, Lauterbach EC, Lovell M, Nussbaum P, Royall DR, Salloway S. Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci* 1997;9:189-197.
9. Cummings JL, Coffey CE, Lauterbach EC, Lovell M, Malloy P, Royall DR, Rummans TA, Salloway S. The clinician-scientist in neuropsychiatry: a position statement from the Committee on Research of the American Neuropsychiatric Association. *J Neuropsych Clin Neurosci* 1998; 10:1-9.
10. Lauterbach E, Cummings J, Duffy J, Coffey CE, Kaufer D, Lovell M, Malloy P, Reeve A, Royall DR, Rummans TA, Salloway S. Neuropsychiatric correlates and treatment of lenticulostratial diseases: a review of the literature and overview of research opportunities in Huntington's, Wilson's, and Fahr's diseases. *J Neuropsych Clin Neurosci* 1998; 10:249-266.
11. Salloway S, Hong J. The CADASIL Syndrome: a genetic form of vascular dementia. *J Geriatric Psychiatry and Neurology* 1998;11:71-77.
12. Rummans T, Lauterbach E, Coffey E, Royall D, Cummings J, Salloway S, Duffy J, Kaufer D. Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled trials. *J Neuropsych Clin Neurosci* 1999;11:176-189.

13. Salloway S, Harrington R, Orr D, LaFrance C. The diagnosis and treatment of dementia in *Psychiatric Care of the Medical Patient* 2nd edition, Stoudemire A, Fogel B, Greenberg D eds. New York, Oxford Press 1999, 597-620. (Book Chapter)
14. LaFrance C, Lauterbach E, Coffey CE, Salloway S, Kaufer D, Reeve A, Royall D, Aylward E, Rummans T, Lowell M. The use of herbal alternative medicines in neuropsychiatry. *J Neuropsych Clin Neurosci* 2000, 12:177-192.
15. Salloway S. Diagnosis and treatment of frontal lobe syndromes in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press, 2001, 139-152. (Book Chapter)
16. Campbell J, Duffy J, Salloway S. Treatment strategies for patients with dysexecutive syndromes, in *The Frontal Lobes and Neuropsychiatric Illness*, Salloway S, Malloy P, Duffy J eds. Washington, D.C., American Psychiatric Press, 2001, 153-166. (Book Chapter)
17. Salloway S, Blitz A. Introduction to functional brain circuitry, *Brain Signaling and Circuitry in Psychiatry*, Kaplan G, Hammer R eds., Amer Psychiatric Publishing 2002, Washington, D.C. 1-29. (Book Chapter)
18. Cohen R, Salloway S, Zawacki P. Disorders of attention In: Yudofsky S, Hales R, eds. *Textbook of Neuropsychiatry*. 4th edition. Washington D.C., American Psychiatric Publishing 2002, 489-524. (Book Chapter)
19. Stopa E, Fallon J, Salloway S, et al. Distribution of smooth muscle actin and agrin in the microvascular of the tg app671, 671. Korczyn ed. 2<sup>nd</sup> International Conference on Vascular Dementia, Monduzzi 2002, 159-163, Bologna.
20. Salloway S, Desbiens S. CADASIL and Other Genetic Causes of Stroke and Vascular Dementia in *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Paul R, Cohen R, Ott B, Salloway S eds. Humana Press, Totowa, NJ, 2004,87-98.
21. Salloway S, Harrington C, Jacobson S. Psychiatric evaluation of the neurologic patient, in Friedman JH, Jeste D. eds. *Psychiatry for Neurologists*. Humana Press, Totowa, NJ 2005, 19-32. (Book Chapter)
22. Salloway S. Improving the diagnosis and treatment of Alzheimer's disease. *Medicine and Health Rhode Island* 2006, 89;5:12-14.
23. Salloway S. Cholinergic treatment across the spectrum: therapeutic trends in mild to severe dementia. *Int Psychogeriatr*. 2006 Sep;18 Suppl 1:S1-2.
24. Cohen R, Salloway S, Sweet L. Neuropsychiatric aspects of disorders of attention In: Yudofsky S, Hales R, eds. *The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences*, 5th edition. Washington D.C., American Psychiatric Publishing 2007, 485-529. (Book Chapter)
25. Salloway S, Brennan-Krohn T, Correia S, Mellion M, delaMonte S. CADASIL: a genetic model of arterial degeneration, white matter injury and dementia. In *Neurobehavior of Dementia*, Miller B and Boeve B eds. Cambridge University Press, Cambridge, UK, 2007, in press.
26. Salloway S. Taking the Next Steps in the Treatment of AD: Disease-Modifying Agents. *CNS Spectrums* 2008;13, suppl 3:11-14.

27. Salloway S. The Prevalence of Alzheimer's Disease: A Growing Crisis, *CNS Spectrums* 2008;13, suppl 3:3.

### BOOKS

1. Salloway S, Malloy P, Cummings J. *The Neuropsychiatry of Limbic and Subcortical Disorders*. American Psychiatric Press Inc., Washington, D.C. 1997.
2. Salloway S, Malloy P, Duffy J. *The Frontal Lobes and Neuropsychiatric Illness*. American Psychiatric Press Inc., Washington, D.C., 2001.
3. Paul R, Cohen R, Ott B, Salloway S eds., *Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management*, Humana Press, Totowa, NJ, 2004.

### OTHER NON- PEER REVIEWED PUBLICATIONS:

1. Salloway S. Book review of *Neurology for the Psychiatry Specialty Board Review*, Weisberg L, *Psychiatric Times* Nov. 1992;44 (Book Review)
2. Salloway S, Duffy J. Neuropsychiatric aspects of depression. *Rhode Island Medicine* 1993; 76:425-430 (invited).
3. Salloway S. Neuropsychiatric aspects of movement disorders. *Rhode Island Medicine* 1993; 76:549-552 (invited).
4. Salloway S, Fowkes V. *Behavioral Science in Primary Care, a teaching manual*, Stanford Press, 1985.
5. Salloway S, *Clinical neuroanatomy and neurochemistry for psychiatrists*. In: Kaufman D., Editor, *Clinical Neurology for Psychiatrists*, Albert Einstein Press, 1991.
6. Salloway S, Faber R. Highlights of the Fifth Annual Meeting of the American Neuropsychiatric Association. *J Neuropsychiatry and Clinical Neurosci* 1993;5:442-3.
7. Salloway S. Review of *Epilepsy and the Quality of Life*. Trimble M, Dodson W. Raven Press 1995 in *Am J Psychiatry* 1996;153:4 (Book Review)
8. Salloway S. Review of *Brain Activation*. Roland P, Wiley Liss 1993 in *J Neuropsychiatry and Clin Neurosci* 1996 (Book Review)
9. Salloway S. CADASIL: A new disease causing subcortical dementia and depression. *Psychiatric Times*, 1997;14:8-9.
10. Harrington C, Salloway S. The diagnosis and treatment of post-stroke depression. *Rhode Island Medicine* 1997;80:181-187.(invited).
11. Salloway S. The nucleus accumbens: a key structure mediating substance abuse and reward. *Psychiatric Times*, 1998; 15:62-4.
12. Salloway S. Clinical applications of brain SPECT scanning in neurology and psychiatry. *Psychiatric Times* 1999; 16:72-74.
13. Heindel W, Salloway S. Memory Systems in the Human Brain. *Psychiatric Times* 1999;16:19-21.
14. Salloway S. The CADASIL syndrome:a genetic cause of small vessel stroke and dementia. *Neurology Network Commentary* 1999;3:40-45.

15. Cahn-Weiner D, Salloway S. Diagnosis and treatment of mild cognitive impairment. *Psychiatric Times* 1999, 9:24-26.
16. Rymer S, Salloway S. Hidden victims of Alzheimer's disease. *Psychiatric Times* 2000;17:44-51.
17. Salloway S. Advances in clinical neuroscience from the AAN 53<sup>rd</sup> Annual Meeting. *Psychiatric Times*, 2001;9:1,10 and 11.
18. Salloway S, Correia S, Peck J, Harrington C. Dementia with Lewy Bodies: A Diagnostic and Treatment Challenge. *RI Medicine* 2002;85(7):207-9.
19. Salloway S. New monoclonal antibody aids diagnosis of CADASIL. *Journal Watch Neurology* 2002;4:20.
20. Salloway S. Features of frontotemporal dementia-3. *Journal Watch Neurology* 2003;5:9.
21. Salloway S. Advances in the treatment of dementia. *The Clinical Advisor*, 2003, in press.
22. Salloway S. Does social isolation influence outcomes after stroke? *Journal Watch Neurology* 2006;8:28.
23. Salloway S. Cholinergic treatment across the spectrum of Alzheimer's disease (Guest Editorial). *Int Psychogeriatrics*, in press, 2006.

#### **CORPORATE AUTHORSHIP OR MULTICENTER TRIALS**

None

#### **PUBLICATIONS SUBMITTED OR IN PREPARATION**

1. Roman G, Royall D, Scheltens P, Doody R, Salloway S, Black S, Kumar, D, Schindler R, Posner H. Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind, randomized, placebo-controlled trial in vascular dementia patients, in preparation.
2. Malone D, Dougherty D, Rezai A, Carpenter L, Friehs G, Eskander E, Rauch S, Rasmussen S, Machado A, Kubu C, Tyrka A, Price L, Stypulkowski P, Giftakis J, Malloy P, Salloway S, Greenberg B. Long-term outcome of deep brain stimulation for highly resistant depression. Submitted to *Biological Psychiatry*.
3. Doody RS, Ferris S, Salloway S, Murthy A, Li MC, Goldman R. Inter-rater reliability between expert and non-expert physicians in the diagnosis of amnesic MCI in the community setting.
4. Doody RS, Ferris S, Salloway S, Murthy A, Goldman R, Xu Y, Sun Y. Donepezil treatment of patients with MCI: a 48 week randomized, placebo-controlled trial.
5. Salloway S, Malloy P, Correia S. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized double-blind, placebo-controlled trials, in preparation.



6. Salloway S, Correia S, Malloy P, Nassery S. Ambulatory blood pressure monitoring in Alzheimer's patients with high and low levels of MRI subcortical hyperintensities, in preparation.
7. Salloway S, Roman G, Correia S, Malloy P. Critical review of the NINDS-AIREN criteria for vascular dementia, in preparation.
8. Salloway S, Krishnan R, Sackheim H, Roose S. Role of MRI subcortical hyperintensities in the treatment response to citalopram in outpatients 75 and older with major depression, in preparation.

### **ABSTRACTS**

1. Campbell J, Duffy J, Salloway S. Apathy and Memory Loss following bilateral anteromedial thalamic infarctions. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446.
2. Salloway S, Malloy P, Rogg J, Duffy J, Kohn R, Richardson E, Gillard E, Thomas C. Subcortical MRI changes in late-life onset depression. *J Neuropsychiatry and Clin Neurosci* 1993; 5:446-447.
3. Campbell J, Salloway S, Duffy J, Malloy P. Utilization behavior and disinhibition in an 82 year old woman. *J Neuropsychiatry and Clin Neurosci* 1994;7:298.
4. Malloy P, Salloway S. Reduplicative paramnesia following lacunar infarction of the right genu of the internal capsule. *J Neuropsychiatry and Clinical Neurosci* 1994;7:317.
5. Salloway S, Dammers P, Eveloff S. REM Sleep Behavior Disorder associated with a cingulate lesion. *J Neuropsychiatry and Clinical Neurosci* 1994; 7:298.
6. Salloway S, Rasmussen S, Brin M, Blitzer A. Laryngeal botulinum toxin injection for refractory vocal tics. *J Neuropsychiatry and Clinical Neurosci* 1994;7:298-299.
7. Salloway S, Malloy P, Rogg J, Duffy J, Kohn R, Thomas C, Richardson E. Clinical significance of subcortical encephalomalacia in early and late onset depression. *Neurology* 1994;44 suppl 2:A375.
8. Salloway S, Rasmussen S, Malloy P. Resolution of longstanding obsessive compulsive disorder following left anteromedial thalamic infarction. *Neurology* 1995;45(suppl 4):A167.
9. Salloway S, Malloy P, Rogg J, Thomas C, Lan J. Neuroimaging Tutorial: A Practical Guide for the Clinician. Accepted for Presentation at the 1995 American Academy of Neurology Annual Meeting but unpublished.
10. Malloy P, Morales X, Salloway S, Richardson E. Sexual delusions: A case series. *J Neuropsychiatry and Clin Neurosci* 1995;7:405.
11. Jenkins M, Malloy P, Salloway S, Biber M. Aphasia and delusions as primary symptoms in a case of multiple sclerosis. *J Neuropsychiatry and Clin Neurosci* 1995;7:404.
12. Chang K, Neeper R, Jenkins M, Penn J, Bollivar L, Israeli L, Malloy P, Salloway S. Clinical profile of patients referred for evaluation of adult attention deficit hyperactivity disorder. *J Neuropsychiatry and Clin Neurosci* 1995;7:400-401.

(American Neuropsychiatric Association Young Investigator Award Honorable Mention).

13. Cahn DA, Malloy P, Salloway S, Rogg J, Gillard E, Kohn R, Tung G, Richardson ED. Subcortical hyperintensities on magnetic resonance imaging and activities of daily living in geriatric depression. *Archives of Clinical Neuropsychology* 1995;11:374. (Presented at the 15th Annual Meeting of the National Academy of Neuropsychology)
14. Jenkins M, Salloway S, Malloy P, Rogg J, Kohn R, Tung G, Richardson E, Gillard E. Frontal subcortical contributions to memory in depressed geriatric patients with periventricular hyperintensities on MRI. *Neurology* 1996;46:A432.
15. Salloway S, Stopa E. Subcortical dementia and depression in biopsy-proven CADASIL: pathological and radiological findings. *Neurology* 1996;46:A326.
16. Jenkins M, Malloy P, Cohen R, Salloway S, Neep R, Penn J, Chang K. Attentional and learning dysfunction among adults with history of childhood ADHD. *J International Neuropsychological Society* 1996;2:209. Presented at International Neuropsychological Society 19th Annual Mid-Year Meeting, Veldhoven, The Netherlands, June 1996.
17. Cohen R, Aloia M, Holler K, Jenkins M, Malloy P, Gordon N, Stone W, Salloway S. Quantitative MRI ratings of subcortical leukoaraiosis in the assessment of dementia: reliability and clinical correlation. *J Neuropsychiatry and Clin Neurosci* 1997;9:134.
18. Westlake R, Jenkins M, Malloy P, Salloway S, Kohn R, Luketela K. Clinical significance of white matter hyperintensities on MRI in geriatric depression. Proceedings of the American Psychiatric Association 1997 Annual Meeting, p. 250. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
19. Jenkins M, Malloy P, Salloway S, Kohn R, Westlake R, Javorsky D. Apathy and activities of daily living in geriatric depressed patients with and without CT scan-identified white matter disease. Proceedings of the American Psychiatric Association 1997 Annual Meeting, p. 249. Poster Presentation in New Research Proceedings of the 1997 American Psychiatric Association Annual Meeting, San Diego, CA, May 1997.
20. Abuelo D, Salloway S. Presymptomatic diagnosis of CADASIL. Proceedings of the American College of Medical Genetics 4th Annual Meeting and the 28th Annual Meeting of the March of Dimes Clinical Genetics Conference. Feb 1997, Ft. Lauderdale, Florida, p. A32.
21. Intal J, Salloway S, Stopa E, Donohue J. MRI-autopsy correlation of signal hyperintensities in leukoencephalopathy. Society of Neuroscience Abstracts 1997, 833. Presented at the 27th Annual Meeting of the Society for Neuroscience, New Orleans.
22. Jenkins M, Hong J, Salloway S, Malloy P, Rickler K, Cohen R. Improvement in attention with stimulant treatment in adults with ADHD. *J Neuropsychiatry Clin Neurosci* 1997, 9:649. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.

23. Tremont G, Stern R, Abuelo D, Geffroy G, Walsh A, Salloway S. Early-onset dementia in a mentally retarded adult associated with novel presenilin-I mutations. *J Neuropsychiatry Clin Neurosci* 1997, 9:697. Presented at the 9th Annual Meeting of the American Neuropsychiatric Association, Honolulu, February 1998.
24. Salloway S, Jenkins M, Intal J, Javorsky D, Malloy P. FLAIR is more sensitive than proton density weighting for visualizing and measuring SH in geriatric hypertension. *J Neuropsych Clin Neurosci* 1999; 11:155. Presented at the 10th Annual Meeting of the American Neuropsychiatric Association in New Orleans, LA.
25. Salloway S, Mega M. The neuropsychiatry of limbic and subcortical disorders. Proceedings of the Third International Neuropsychiatry Congress. Kyoto, Japan, April 2000.
26. Jenkins M, Salloway S, Malloy P, Hong J, McKiernan K. Effects of stimulant treatment for adult ADHD on executive functioning. *J Neuropsych Clin Neurosci* 2001;13:133. Presented at the 12<sup>th</sup> Annual Meeting of the American Neuropsychiatric Association, Ft. Myers, FL.
27. LaFrance C, Salloway S, Greenberg B. Obsessive Compulsive Symptoms, Mood and Laterality in Patients with Spasmodic Torticollis. *Movement Disorders* 2001;16(Sup 1):S48. Presented at the First International Congress of Behavioral Dysfunction in Movement Disorders October 2001, Montreal, Canada.
28. Stopa E, Fallon J, Salloway S, Butala P, Zipser B, Morales X, Hovanesian V, Hulette C, Rosenberg C, Tavares R, Johanson C, Vitek M. Differential distribution of smooth muscle actin and agrin in the microvasculature of the tg app670, 671 mouse and alzheimer brain.. *Society of Neuroscience Abstracts* 2001, in press. Presented at the 31<sup>st</sup> Annual Meeting of the Society for Neuroscience, San Diego, CA, November 2001.
29. Salloway S, Stopa E, Douglas F, Wilterdink J, Rogg J. Amyloid angiopathy associated with cerebral hemorrhage, extensive microhemorrhages and severe white matter edema. Presented at the 2<sup>nd</sup> International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
30. Salloway S, Boyle P, Malloy P, Correia S, Krishnan R, Schneider L, Cahn-Weiner D, Nakra R. MRI subcortical hyperintensities in outpatient geriatric major depression: information from two recent randomized, prospective placebo controlled trials. Presented at the 2<sup>nd</sup> International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
31. Gur T, Stopa E, Fallon J, Salloway S. Effect of APOE4 genotype on capillary basement membrane area in Alzheimer's disease. Presented at the 2<sup>nd</sup> International Conference on Vascular Dementia, January 2002, Salzburg, Austria.
32. Boyle P, Malloy P, Salloway S. Frontal lobe function and the predictors of functional abilities in patients with dementia. *JINS* 2001;7(4):486. Presented at the Annual Meeting of the International Neuropsychological Association, February 2001, Chicago, IL.
33. MacLean, A, Salloway S, Woods R, Stopa E, Douglas F, Wilterdink J, Rogg J. Novel findings in two cases of biopsy-proven small artery disease: Spontaneous

- cerebral hemorrhage in CADASIL and severe white matter edema in amyloid angiopathy. *Neurobiology of Aging* 2002;23(1S):S172. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden
34. Salloway S, Pratt RD, Perdomo CA and The Donepezil 308 VaD Study Group. Donepezil treated patients with vascular dementia demonstrate cognitive and global benefits. *Neurobiology of Aging* 2002;23(1S):S57. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
  35. Malloy P, Rymer S, Salloway S, Lauren Norton. Contributions to caregiver burden in Alzheimer's disease: awareness of deficit and behavioral disturbance. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
  36. Correia S, Salloway S, Boyle P, Malloy P, Cahn-Weiner D, Scheider L, Krishnan RR, Nakra R. Relationship of subcortical hyperintensities to treatment response in young and old elderly with outpatient geriatric depression: Results of two placebo-controlled trials. *Neurobiology of Aging* 2002;23(1S):S159. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
  37. Boyle P, Malloy P, Salloway S, Correia S. Functional significance of subcortical white matter changes in Alzheimer's disease. *Neurobiology of Aging* 2002;23(1S):S495. Presented at the World Alzheimer Congress July 2002, Stockholm, Sweden.
  38. Salloway S, Gustavo Roman G. Critical review of the NINDS-AIRENS Vascular Dementia Criteria. Presented at the Alzheimer's Imaging Consortium, July 2002, Stockholm, Sweden.
  39. Salloway S, Pratt R, Perdomo CA. Donepezil improves cognition in patients with probable and in those with possible vascular dementia. *Eur J Neurol* 2002;9(suppl 2):192(p3114). Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
  40. Salloway S, Pratt R, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia and Alzheimer's disease. Presented at the European Federation of Neurological Societies, October 2002, Vienna, Austria.
  41. Salloway S, Richardson S, Ferris S, Kluger A. Benefits of donepezil treatment in patients with mild cognitive impairment. American Academy of Neurology 55<sup>th</sup> Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A411-2
  42. Correia S, Salloway S, Roman G. Critical review of the NINDS-AIREN criteria for vascular dementia. American Academy of Neurology 55<sup>th</sup> Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A377-8.
  43. Salloway S, Malloy P, Correia S. A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: a subanalysis of two 24-week, randomized double-blind, placebo-controlled trials. American Academy of Neurology 55<sup>th</sup> Annual Meeting, April 2003, Honolulu. *Neurology* 2003;60:A141-2.

44. Salloway S, Richardson S. Donepezil treatment provides benefits in patients with mild cognitive impairment. International Psychogeriatric Association 11<sup>th</sup> International Congress, Chicago, August, 2003, *International Psychogeriatrics* 2003;15, suppl 2:107.
45. Correia S, Salloway S, Belanger H, Nassery S, Malloy P, Drodge S. Ambulatory blood pressure monitoring in Alzheimer's disease patients with high and low degree of subcortical hyperintensities. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:150-1.
46. Salloway S, Pratt RD, Perdomo CA. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia. First Congress of the International Society for Vascular Cognitive and Behavioral Disorders, Gothenberg Sweden, August, 2003. *J Neurol Sci* 2004;226:160-161.
47. Miaux Y, Guermazi A, Salloway S, Sieffert M, Altman H, Pratt R. Neuroradiological Features Associated with Vascular Dementia. European Society of Neuroradiology. Istanbul Turkey, September 2003.
48. Guermazi A, Miaux Y, Sieffert M, Salloway S, Altman, Pratt R. Neuroradiological findings in vascular dementia. Radiological Society of North America 89<sup>th</sup> Annual Meeting, Chicago November 2003.
49. Tremont G, Davis J, Slavin C, Bishop D, Salloway S. Family Functioning as a Predictor of Burden in Caregivers of Patients with Mild to Moderate Dementia. International Neuropsychological Association 32<sup>nd</sup> Annual Meeting Baltimore, MD, February, 2004. *JINS* 2004, in press.
50. Salloway S, Mahableschwarkar A, Brashear R. Differential efficacy of galantamine in patients with dementia and cerebrovascular disease:a subanalysis by CVD lesion subtypes. Presented at the 42<sup>nd</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2003.
51. Wilder-Willis, KE, Malloy, PF, Salloway, S, Correia, S, Belanger, HG, Kumariah, D, Flynn-O'Brien, K. Performance on the delayed response and delayed matching to sample task in patients with mild cognitive impairment and healthy elderly controls. International Neuropsychological Association 32<sup>nd</sup> Annual Meeting Baltimore, MD, February 2004. *JINS* 2004, in press.
52. Salloway S, Ieni J, Griesing T, Goldman R, Kluger A, Kumar D, Richardson S. Cognitive response in patients with amnesic mild cognitive impairment: benefits of donepezil. American Association of Geriatric Psychiatry 17<sup>th</sup> Annual Meeting, February, 2004 Baltimore, MD.
53. Laidlaw, DH, Zhang S, Bastin ME, Correia S, Salloway S, Malloy P. Ramifications of isotropic sampling and acquisition orientation on DTI analyses. International Society of Magnetic Resonance in Medicine, Tokyo, Japan, May 2004.
54. Auchus A, Brashear HR, Salloway S, Scheltens P, Korczyn A, Gassman-Mayer C, Gold M. Results of a trial of galantamine subjects with vascular dementia confirmed by a central reading. *Neurology* 2004; American Academy of Neurology Annual Meeting, San Francisco, CA, April 2004.

55. Davis J, Tremont G, Slavin C, Salloway S. Caregiver perception of executive dysfunction and behavioral problems as predictors of burden in dementia caregivers. *Journal of Neuropsychiatry and Clinical Neurosciences*. in press; Paper presented at the 2004 Meeting of the American Neuropsychiatric Association, Bal Harbour, FL
56. Correia S, Zhang S, Laidlaw D, Malloy P, Salloway S. (2004) Diffusion-tensor imaging: linear, planar, and spherical diffusion in CADASIL. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. Abstract P2-232 *Neurobiology of Aging* 2004;25(S2):S298.
57. Correia S, Salloway S, Malloy P, Song C, Li R. (2004) Systolic Blood Pressure Variability and Subcortical Hyperintensities in Patients with Mild-To-Moderate Alzheimer's Disease. Poster. 9th International Conference on Alzheimer's Disease and Related Disorders, July 17-22, Philadelphia. *Neurobiology of Aging* 2004;25(S2):S278
58. Malloy PF, Belanger H, Hall S, Grigsby J, Hamman RF, Wilder-Willis K, Aloia M, Salloway S. Validation of Measures of Spatial and Executive Abilities in Alzheimer's Disease and Mild Cognitive Impairment. Poster. 9<sup>th</sup> International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S112.
59. Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Donahue JE, Hulette CM, Vitek MP, Stopa EG. Microvascular Damage in Alzheimer's disease. Poster. 9<sup>th</sup> International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17-22, 2004. *Neurobiology of Aging* 2004; 25(S2): S408.
60. Salloway S, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12-18 months maintain cognitive benefits. Presented at the 8<sup>th</sup> Congress of the European Federation of Neurological Societies. Paris, France, September, 2004. *European Journal of Neurology* 2004;11 suppl 2,184.
61. Correia S, Brennan-Krohn T, Zhang S, Laidlaw D, Malloy P, Salloway S. Diffusion-Tensor Imaging and Executive Function in Subcortical Ischemic Vascular Disease and Mild Cognitive Impairment. Presented at the International Neuropsychological Association 33<sup>nd</sup> Annual Meeting St. Louis, MO, February 2005. *JINS* 2005, in press.
62. Salloway S, Ferris S, Kluger A, Goldman T, Griesing T, Kumar D, Richardson S. Key lessons learned from the design and outcome of a 24 week donepezil mild cognitive impairment trial. Cold Spring Harbor Laboratory Mechanisms of Drug Discovery in Neurodegenerative Disorders Conference, Cold Spring Harbor, NY, December, 2004.
63. Brennan-Krohn T, Dong M, Rivera E, Salloway S, delaMonte S,. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. Presented at the NIMH Summer Training in Aging Research Topics Mental Health Annual Conference, San Diego, CA, August, 2005.

64. Correia S, Lee S, Malloy P, Mehta N, Zhang S, Salloway S, Laidlaw DH. Diffusion-Tensor MRI Tractography Methods For Assessing White Matter Health And Its Relationship To Cognitive Functioning. International Neuropsychological Society 34th Annual Meeting, Boston, February 2006
65. Lee SY, Correia S, Tate DF, Paul RF, Zhang S, Salloway SP, Malloy PF, and Laidlaw DH. Quantitative Tract-of-Interest Metrics for White Matter Integrity Based on Diffusion Tensor MRI Data. Oral Presentation. 14<sup>th</sup> International Society for Magnetic Resonance in Medicine Scientific Meeting & Exhibition, Seattle, Washington, May 2006
66. Vascular Dementia and Vascular Cognitive Impairment: Treatment Approaches. *Brain and Cognition* 2006, in press.
67. Correia S, Lee S, Zhang S, Salloway SP, Malloy PF, Laidlaw DH. Diffusion-tensor imaging tractography: correlation with processing speed in aging. *Alzheimer's and Dementia* 2006;Vol 2,#3:S317-8, S686. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD) (Best Poster Award)*. Madrid, Spain, July, 2006.
68. Brennan-Krohn T, Dong M, Rivala E, Salloway S, delaMonte S. CADASIL: Molecular Analysis of Aberrant Gene Expression in the Brain. *Alzheimer's and Dementia* 2006;Vol 2,#3:S564-5. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD)*. Madrid, Spain, July, 2006.
69. Davis C, Salloway S, Doody R, McRae T, Kumar D, Posner H, Surick I. Safety findings from the donepezil vascular dementia program. *Alzheimer's and Dementia* 2006;Vol 2,#3 in press. Presented at the *10th International Conference on Alzheimer's Disease and Related Disorders (ICAD)*. Madrid, Spain, July, 2006.
70. Patel K., Correia S, Foley J, Schlicting E, Zhang S, Laidlaw D, Salloway S. Cognitive impairment, hippocampal volume, and white matter integrity in CADASIL. 35<sup>th</sup> Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
71. Schlicting E, Correia S, Malloy P, Salloway S. N-back performance and standardized measures of processing speed, executive function, and working memory in mild cognitive impairment vs. normal controls. 35<sup>th</sup> Meeting of the International Neuropsychological Society, Portland OR, February 7-10, 2007.
72. Brennan-Krohn T, Dong M, Rivala E, Salloway S, delaMonte S. Aberrant Gene Expression in the Brain in CADASIL. *Neurology* 2007, in press. Presented at the 59<sup>th</sup> Annual Meeting of the American Academy of Neurology, Boston, MA, May, 2007.
73. Correia S, Foley J, Zhang S, Laidlaw D, Malloy P, Salloway S. Processing speed in CADASIL: Relationship to cingulum vs. callosal fibers. Presented at the Third Congress of the International Society for Vascular Cognitive and Behavioral Disorders, San Antonio, Texas, July, 2007.

74. Patel K, Correia S, Epstein S, Schlicting S, Zhang S, Laidlaw D, Malloy P, Salloway S. Grey and white matter changes on MRI and diffusion-tensor imaging and cognitive function in mild cognitive impairment. (2008). Paper presentation. 36<sup>th</sup> Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
75. Song S, Correia S, Schlicting S, Malloy P, Salloway S. Executive impairment and MoCA performance in mild cognitive impairment and Alzheimer's disease (2008). Poster abstract. 36<sup>th</sup> Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008.
76. Schlicting E, Correia S, Malloy P, Salloway S. Classification of patients with amnesic mild cognitive impairment vs. normal controls based on N-back, Self-Ordered Pointing Task, and standardized cognitive measures. Poster abstract. 36<sup>th</sup> Meeting of the International Neuropsychological Society, Waikoloa, Hawaii, February 6-9, 2008
77. Dichgans M, Markus H, Salloway S, Moline M, Hsu T, Posner H, Hurt S, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL: A model of subcortical vascular cognitive impairment. American Heart Association International Stroke Congress, February, 2008.
78. Doody R, Ferris S, Salloway S, Murthy A, Goldman R, Xu Y, Sun Y. A 1 year randomized trial of donepezil in patients with mild cognitive impairment. 10<sup>th</sup> International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy. Hong Kong, China February, 2008.
79. Salloway S, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. Efficacy and tolerability of donepezil in CADASIL. 60<sup>th</sup> Annual Meeting of the American Academy of Neurology Late Breaking Science. Chicago, IL, April, 2008.
80. Chabriat H, Markus H, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Dichgans M. Donepezil improves executive function in non-demented CADASIL patients. 17<sup>th</sup> European Stroke Conference, Nice, France, May, 2008.
81. Salloway S, Dichgans M, Markus H, Moline M, Posner H, Wang Q, Chabriat H. 18 week placebo-controlled trial of donepezil for treatment of cognitive impairment in CADASIL. International Congress of Alzheimer's Disease 2008, Chicago, IL, July, 2008.

### **SCHOLARLY WORK PUBLISHED IN OTHER MEDIA:**

#### **Educational Videotapes and CD-ROMs**

1. Between a Rock and a Hard Place-Ethical Decision-Making in the Hospital-a training film for medical students. Sachs J Director. Palo Alto, CA, Stanford Video Productions, 1985.
2. Salloway S. Intensive Review of Neurology. Irvine, CA, CME Inc. 1996.
3. Salloway S. Treatment of Fragile Elderly. Houston, TX, American Medical Communications. 1996.



4. Salloway S. Vascular Dementia CD ROM-A Unique Disease Entity or a Variation of Alzheimer's Disease. Innovia Education Institute Columbia, MD, 2003.
5. Salloway S. Advances in the Diagnosis and Treatment of Vascular Dementia in Highlights of the 2<sup>nd</sup> Annual Dementia Congress: An Interactive CME Activity on CD-ROM, Academy for Health Care Education, New York, New York, 2004.
6. Salloway S. Management of Early Dementia. CD-Pharma Productions, Montreal, CA November, 2005.
7. Salloway S. Advances in Mild Cognitive Impairment and Alzheimer Disease. CD ROM. Clinical Geriatrics/Center for Biomedical Communication Inc., December, 2005.
8. Salloway S. Diagnosis and Treatment of Mild Cognitive Impairment: Now and in the Future. CD ROM. Highlights of the Fifth Annual Dementia Congress. Academy for Health Care Education Inc., New York, NY, 2007.